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A recent Correspondence proposed the neurohormone oxytocin as a defence for COVID-19 
(1). This is one of a handful of papers in the academic literature (2-4) providing patterns and 
mechanisms to support oxytocin as an intervention for COVID-19. We propose an addition-
al arrow in the quiver of oxytocin's non-classical functions. 
Our hypothesis is that oxytocin may have direct antiviral effects against SARS-CoV-2. 
Dipeptidyl peptidase-4 (DPP4) protease inhibitors have been proposed as a treatment for 
Middle Eastern respiratory syndrome coronavirus and COVID-19 (5) and oxytocin happens 
to be a natural DPP4 inhibitor (6), therefore it is not unreasonable to propose that oxytocin 
could inhibit other proteases.  
There are three papers that raise the possibility that oxytocin could be an antiviral against 
SARS-CoV-2 via other targets. The first two papers (7,8) identify oxytocin as one of the 
FDA drugs that could inhibit the SARS-CoV-2 main protease. The third paper (9) raises the 
possibility that oxytocin analogues, an oxytocin antagonist and a vasopressin analogue are 
inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase. We suggest that this rais-
es the possibility that oxytocin, with its similar structure, could also be an inhibitor of some 
of these enzymes. 
Future research is needed to confirm if oxytocin is a direct antiviral via inhibition of the 
SARS-CoV-2 main protease, other viral targets or if it inhibits transmembrane serine pro-
tease 2 (TMPRSS2) for instance. 
Even if oxytocin does not have direct antiviral effects it still has sufficient mechanisms that 
could make it effective against COVID-19 such as immunomodulatory, cardioprotective, 
anti-diabetic and anabolic functions as well as psycho-social functions (10). 
Increasing endogenous oxytocin could increase viral resistance and increase general 
health especially in vulnerable population groups. Oxytocin can be administered as an ex-
ogenous drug in multiple ways; however, oxytocin in solution requires consistent refrigera-
tion. The more recent development of a dry inhaler makes oxytocin available to the whole 
world. 
Therefore, if oxytocin is identified as a true antiviral it would make oxytocin the single most 
effective defence and treatment for COVID-19, helping us turn the tide in this global war 
and helping us stop the Second Wave that threatens to overwhelm us. Oxytocin may be the 
Achilles heel of a seemingly invulnerable enemy. 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